Please login to the form below

Not currently logged in
Email:
Password:

Reata

This page shows the latest Reata news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

Reata Pharma success in kidney disease treatment. Reata Pharmaceuticals has produced phase II results showing its bardoxolone methyl (bardoxolone) can prevent or dealy kidney failure in a rare form of chronic ... Reata collected historical eGFR data for

Latest news

  • Abbott agrees $400m chronic disease deal with Reata

    The pharma company will make a one-off payment of $400m to Texas, US-based Reata Pharmaceuticals for its second-generation oral antioxidant inflammation modulators (AIMs). ... For these conditions, Abbott will take 70 per cent of costs and profits, while

  • Regional plans

    A similar rationale applies to the deal between Abbott and Reata where Abbott will be providing the global marketing capability outside the US. ... Platform. 480. PregLem/Richter. Corporate acquisition.  . 461. Reata/Abbott. Bardoxolone for chronic

  • Abbott signs kidney drug deal

    Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase II drug for chronic kidney disease. ... Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase II drug for chronic kidney

  • Advancing acquisitions

    P1 . 334. Reata Pharma/Kyowa Hakko . Bardoxolone in chronic kidney disease. P2a .

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics